 |
PDBsum entry 4x6m
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
4x6m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.27
- coagulation factor XIa.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
25:1635-1642
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
|
|
D.J.Pinto,
J.M.Smallheer,
J.R.Corte,
E.J.Austin,
C.Wang,
T.Fang,
L.M.Smith,
K.A.Rossi,
A.R.Rendina,
J.M.Bozarth,
G.Zhang,
A.Wei,
V.Ramamurthy,
S.Sheriff,
J.E.Myers,
P.E.Morin,
J.M.Luettgen,
D.A.Seiffert,
M.L.Quan,
R.R.Wexler.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Compound 2 was previously identified as a potent inhibitor of factor XIa lacking
oral bioavailability. A structure-based approach was used to design analogs of 2
with novel P1 moieties with good selectivity profiles and oral bioavailability.
Further optimization of the P1 group led to the identification of a
4-chlorophenyltetrazole P1 analog, which when combined with further
modifications to the linker and P2' group provided compound 32 with FXIa
Ki=6.7nM and modest oral exposure in dogs.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |